Trial Profile
A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Binimetinib (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions
- Sponsors Array BioPharma; Novartis
- 20 Mar 2018 Status changed from active, no longer recruiting to completed.
- 22 Dec 2017 Planned End Date changed from 31 Dec 2017 to 31 Dec 2018.
- 26 May 2017 Planned End Date changed from 30 Jun 2017 to 31 Dec 2017.